🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

91 results for “standard” Clear

  1. A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  2. A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  3. A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma

    Lacuna Pharma Pty Ltd

    Glioblastoma multiforme (GBM)

    phase 1 other active

    1 trial

  4. A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

  5. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  6. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy

    AstraZeneca AB

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  7. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  8. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  9. A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments.

    Fondazione Telethon ETS

    Hepatocellular carcinoma

    phase 1 other active

    1 trial

  10. An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 1 other active

    1 trial

  11. Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months

    United Therapeutics Europe Ltd

    Head and Neck Fibrosis

    phase 1 other completed

    1 trial

  12. BMP-655/ACS+Standard of care or Standard of care

    Pfizer

    Rotator Cuff Tear

    phase 1 mab terminated

    1 trial

  13. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  14. Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (High Fat High Calorie Meal and Standard Meal).

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  15. Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumors

    phase 1 small molecule active

    1 trial

  16. Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD

    Topiloric/Uriadec

    chronic liver disease

    phase 1 other active

    1 trial

  17. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  18. Standardized Research E-cigarette (SREC)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking, Cigarette

    phase 1 small molecule active

    1 trial

  19. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  20. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  21. standard care

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 other terminated

    1 trial

  22. standard chemotherapy medicine combined with Chinese herbs

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  23. standard dose capecitabine

    Karyopharm Therapeutics Inc

    Rectal Neoplasms

    phase 1 small molecule active

    1 trial

  24. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources